ADMP
No questioning BobStocks succinct and accurate analysis that this one's a real poodle. Can't help you with the cash numbers. This is from their latest 8-k:
The Company is reviewing the CRL and plans to request a meeting with the FDA to discuss the CRL. Depending in part on the results of subsequent communications with the FDA, development of a protocol acceptable to the FDA for the additional studies, and the results of any additional studies that the Company may conduct, the Company believes that it can complete the additional testing and submit the results to the FDA sometime in the second half of 2016, although there can be no assurances that this will be the case.
And this is from their post CRL PR:
The Company believes that it can finalize the study protocols with the FDA and complete the additional testing within a relatively short period of time at an immaterial cost, and submit the data back to the FDA sometime in the second half of 2016.
It's quite understandable that this management has lost all credibility with both the big end of the street and retail.
In general, these are some tough days for bounce plays in the market, but especially in bio's.
My plan is to hold shares through the next FDA approval run up, which I have to believe will exceed my cost basis of $3.70.
Also added RVNC today at $13.40; again, willing to hold for a year.
News 
Market Data 
Discover 
